<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Vivorté Cites BioMedGPS in the FORTERA and REGENTO bone grafting solutions Release

Posted by Sharon O'Reilly on 10/20/17 9:01 AM

Vivorte.pngVivorté, Inc., a vertically-integrated, specialty orthopedic biomaterials company, announced the commercial availability of a complete line of bone grafting product solutions.

Citing BioMedGPS SmartTRAK, Vivorté, Inc. wrote "According to BioMedGPS, the current market for bone graft substitute products exceeds $1.7B annually in the United States alone." Read the Release: "Vivorté announces the commercial availability of FORTERA and REGENTO bone grafting solutions for orthopedic surgery" 

 Subscribe to Blog


Topics: Orthopedics-OrthoBio

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts